BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 19068202)

  • 1. [Expansion of human natural killer cells ex vivo].
    Huang QS; Li Q; Huang Y; Shang P; Zhang MJ
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2008 Dec; 24(12):1167-9. PubMed ID: 19068202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ex vivo expansion of natural killer cells for clinical applications.
    Klingemann HG; Martinson J
    Cytotherapy; 2004; 6(1):15-22. PubMed ID: 14985163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ex vivo expansion of natural killer cells with high cytotoxicity by K562 cells modified to co-express major histocompatibility complex class I chain-related protein A, 4-1BB ligand, and interleukin-15.
    Gong W; Xiao W; Hu M; Weng X; Qian L; Pan X; Ji M
    Tissue Antigens; 2010 Dec; 76(6):467-75. PubMed ID: 20670353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential expansion of umbilical cord blood mononuclear cell-derived natural killer cells dependent on the dose of interleukin-15 with Flt3L.
    Nagamura-Inoue T; Mori Y; Yizhou Z; Watanabe N; Takahashi TA
    Exp Hematol; 2004 Feb; 32(2):202-9. PubMed ID: 15102482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ex vivo expansion of natural killer cells using cryopreserved irradiated feeder cells.
    Baek HJ; Kim JS; Yoon M; Lee JJ; Shin MG; Ryang DW; Kook H; Kim SK; Cho D
    Anticancer Res; 2013 May; 33(5):2011-9. PubMed ID: 23645750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy.
    Tam YK; Martinson JA; Doligosa K; Klingemann HG
    Cytotherapy; 2003; 5(3):259-72. PubMed ID: 12850795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Wilms tumor cell line, HFWT, can greatly stimulate proliferation of CD56+ human natural killer cells and their novel precursors in blood mononuclear cells.
    Harada H; Watanabe S; Saijo K; Ishiwata I; Ohno T
    Exp Hematol; 2004 Jul; 32(7):614-21. PubMed ID: 15246157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The correlation between the percent of CD3- CD56+ cells and NK precursor function.
    Gharehbaghian A; Donaldson C; Newman J; Bannister G; Bradley BA
    Iran J Allergy Asthma Immunol; 2006 Dec; 5(4):167-75. PubMed ID: 17237569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of cyclosporin A on interleukin-15-activated umbilical cord blood natural killer cell function.
    Lin SJ; Kuo ML
    Cytotherapy; 2008; 10(4):397-405. PubMed ID: 18574772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-15 supports generation of highly potent clinical-grade natural killer cells in long-term cultures for targeting hematological malignancies.
    Suck G; Oei VY; Linn YC; Ho SH; Chu S; Choong A; Niam M; Koh MB
    Exp Hematol; 2011 Sep; 39(9):904-14. PubMed ID: 21703984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expansion of natural killer cells with lytic activity against autologous blasts from adult and pediatric acute lymphoid leukemia patients in complete hematologic remission.
    Torelli GF; Guarini A; Maggio R; Alfieri C; Vitale A; Foà R
    Haematologica; 2005 Jun; 90(6):785-92. PubMed ID: 15951291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Method for expansion in vitro of CD3-CD56+CD16+NK cells highly purified from human peripheral blood].
    Xiong D; Yang ZG; Li QH; Wu ZC; Lü JT
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Oct; 18(5):1310-5. PubMed ID: 21129283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expansion of NK Cells Using Genetically Engineered K562 Feeder Cells.
    Phan MT; Lee SH; Kim SK; Cho D
    Methods Mol Biol; 2016; 1441():167-74. PubMed ID: 27177665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
    Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A
    J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimized protocols for generation of cord blood-derived cytokine-induced killer/natural killer cells.
    Li Y; Schmidt-Wolf IG; Wu YF; Huang SL; Wei J; Fang J; Huang K; Zhou DH
    Anticancer Res; 2010 Sep; 30(9):3493-9. PubMed ID: 20944128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of interleukin-15 and Flt3-ligand on natural killer cell expansion and activation: umbilical cord vs. adult peripheral blood mononuclear cells.
    Lin SJ; Yang MH; Chao HC; Kuo ML; Huang JL
    Pediatr Allergy Immunol; 2000 Aug; 11(3):168-74. PubMed ID: 10981526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.
    Klöß S; Oberschmidt O; Morgan M; Dahlke J; Arseniev L; Huppert V; Granzin M; Gardlowski T; Matthies N; Soltenborn S; Schambach A; Koehl U
    Hum Gene Ther; 2017 Oct; 28(10):897-913. PubMed ID: 28810809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
    Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
    Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expansion of Valpha24(+)Vbeta11(+) NKT cells from cord blood mononuclear cells using IL-15, IL-7 and Flt3-L depends on monocytes.
    Okada H; Nagamura-Inoue T; Mori Y; Takahashi TA
    Eur J Immunol; 2006 Jan; 36(1):236-44. PubMed ID: 16380959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ex vivo expansion of dendritic-cell-activated antigen-specific CD4+ T cells with anti-CD3/CD28, interleukin-7, and interleukin-15: potential for adoptive T cell immunotherapy.
    Chen HW; Liao CH; Ying C; Chang CJ; Lin CM
    Clin Immunol; 2006 Apr; 119(1):21-31. PubMed ID: 16406844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.